<p>Iron oxide is the most common catalyst in solid rocket propellant. We have previously demonstrated increased performance of propellant by encapsulating iron oxide particles within ammonium perchlorate (AP), but only nanoscale particles were used, and encapsulation was only accomplished in fine AP (~20 microns in diameter). In this study, we extended the size of particle inclusions to micron-scale within the AP particles as well the particle sizes of the AP-encapsulated catalyst particles (100s of microns) using fractional crystallization techniques with the AP-encapsulated particles as nucleation sites for precipitation. Here we report catalyst particle inclusions of micron-scale, as well as nanoscale, within AP and present characterization of this encapsulation. Encapsulating micron-sized particles and growing these composite particles could pave the way for numerous possible applications. A study of the thermal degradation of these AP-encapsulated particles compared against a standard mixture of iron oxide and AP showed that AP-encapsulated micron-scale catalyst particles exhibited similar behavior to AP-encapsulated nanoscale particles. Using computed tomography, we found that catalyst particles were dispersed throughout the interior of coarse AP-encapsulated micron-scale catalyst particles and decomposition was induced within these particles around catalyst-rich regions.</p>

In human pregnancy, the feto-placental vessels are crucial for efficient materno-fetal transfer; hence they play a pivotal role in the pathogenesis of fetal growth restriction (FGR). We, as well as other research groups, have observed abnormalities in the FGR feto-placental vasculature, which, though inconclusive, were suggestive of a state of panhypovascularity. The goal of the work presented in this thesis was to investigate this. We hypothesised that the placenta may be panhypovascular in FGR due to failed angiogenesis; and enhancing angiogenesis in the placenta may improve fetal growth. Custom-designed techniques including advanced imaging, computer-aided analyses and tube-forming experiments were employed to compare feto-placental vessels and endothelial cells in placentas from normal and FGR-complicated pregnancies while aiming to answer two main research questions: (i) is the FGR placenta panhypovascular? (ii) can angiogenesis be induced or enhanced to improve placental vascularity?Findings include: (i) shorter arterial [p = 0.03 and 0.009 when data adjusted for placental surface area (PA) and weight (PW) respectively] and longer venous path [p = 0.05 and 0.03, adjusted for PA and PW respectively] in FGR placentas though no difference in the total number of arterial or venous branches, diameter, and tortuosity of the vessels compared to normal; (ii) altered angiogenic behaviour/response of FGR placental endothelial cells following in vitro pharmacological manipulation of WNT signalling; (iii) human placental endothelial cells are capable of regaining their angiogenic potential following withdrawal of WNT inhibition. These findings discount the hypothesis of panhypovascularity in FGR placentas, but identify additional, previously unreported, feto-placental vascular abnormalities associated with FGR. Also, the findings provide evidence that impairment of WNT signalling may play a role in defective angiogenesis and consequent dysvascularity in the FGR placenta. The evidence suggests the WNT pathway should be explored as a potential new target for therapeutic interventions to correct placental dysvascularity in FGR.